NCT06083922 - A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Multiple MyelomaMonoclonal Gammopathy of Renal Significance

Interventions

DRUG

Cyclophosphamide

Days 1, 8 and 15, Cycles 1-8

DRUG

Bortezomib

Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+

DRUG

Dexamethasone

Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8

DRUG

Daratumumab

Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+

Trial Locations (11)

10021

NOT_YET_RECRUITING

Weill Cornell Medical Center (Data Collection Only), New York

10029

NOT_YET_RECRUITING

Mount Sinai Hospital (Data Collection Only), New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack

27514

RECRUITING

University of North Carolina (Data Collection Only), Chapel Hill

02111

RECRUITING

Tufts Medical Center (Data Collection Only), Boston

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale